RxDoctor Payments Data

Patrick Campbell, MD

Advanced Heart Failure and Transplant Cardiology · Little Rock, ARNPI 1215113154

Payments from drug & device makers

$185,992in general payments, 2019–2025

Across 1,047 payments — averaging $177.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$48K
  • Pfizer$46K
  • Alnylam Pharmaceuticals Inc.$26K
  • Novartis$14K
  • Boehringer Ingelheim$11K
  • Actelion Pharmaceuticals US, Inc.$9K
  • plus $32K from 39 others

What the payments were for

  • Consulting fees$12,58012%
  • Speaking & faculty fees$56,98056%
  • Travel & lodging$9,1089%
  • Food & beverage$22,92822%
  • Education$6661%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$124,622
Medicare patients
243
Services billed
1,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan156$1,957,109
UptraviSelexipag51$1,117,393
VyndamaxTafamidis32$935,982
AdempasRiociguat50$702,286
Tyvaso DpiTreprostinil28$654,707
Orenitram ErTreprostinil Diolamine27$417,056
CamzyosMavacamten28$234,621
EntrestoSacubitril/Valsartan262$219,763
WinrevairSotatercept-Csrk11$163,722
JardianceEmpagliflozin144$115,830
DalvanceDalbavancin Hcl25$87,641
EliquisApixaban86$71,211
Sirolimus47$55,648
TrulicityDulaglutide33$30,407
FarxigaDapagliflozin Propanediol36$26,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$9,302$3,074,502207 claims
PfizerVyndamax, Eliquis$46,110$1,007,193118 claims
BayerAdempas$1,934$702,28650 claims
E.r. Squibb & Sons, L.L.C.Camzyos$582$234,62128 claims
NovartisEntresto$13,977$219,763262 claims
MerckWinrevair$970$163,72211 claims
Boehringer IngelheimJardiance$10,649$115,830144 claims
AbbVieDalvance$22$87,64125 claims
Lilly USA, LLCTrulicity$5,227$30,40733 claims
AstraZenecaFarxiga$1,454$26,41236 claims
Johnson & JohnsonXarelto$75$20,81225 claims
Novo NordiskWegovy$193$18,17813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Little Rock

Where these figures come from

Is this you, or does something look wrong? →